The Food and Drug Administration has approved Zarxio (filgrastim-sndz), a biosimilar to filgrastim (Neupogen, marketed by Amgen Inc.). The drug binds to the granulocyte colony-stimulating factor (G-CSF) receptor, and is widely prescribed to treat neutropenia. The approval of Zarxio is...
Europe, Japan and Australia. Sandoz currently markets three biosimilars (somatropin, filgrastim and epoetin alfa) outside the US; each of which occupies the #1 biosimilar position in its respective
Second Filgrastim Biosimilar Gets Thumbs Up From the FDA Survivor's Story Foreshadows One of Oncology's Greatest Successes Tools Drug Interaction Checker Pill Identifier Calculators Formulary Drug Class Hematopoietic Growth Factors Slideshow Hematology-Oncology Guidelines: 2017 Midyear Review Recommended...
Raedler LA, Zarxio RLA. Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States. Am Health Drug Benefits 2016;9:150-4.Raedler LA. Zarxio (filgrastim-sndz): first biosimilar approved in the United States. Am Health Drug Benefits. 2016;9(Spec Feature): 150-154....
FDA Approves First Biosimilar for U.S.—Zarxio (Filgrastim-sndz)An abstract is unavailable.DiGiulioSarah
Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post-Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia ProphylaxisRush, CassandraSabus, Ashley...
Cost-efficiency analyses for the US of biosimilar filgrastim-McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of ...
cost savings through use of filgrastim-sndz over reference filgrastim from a Medicare breast cancer patient perspective.Methods: An Excel simulation analysis was conducted among breast cancer patients treated with biosimilar filgrastim-sndz or the branded reference filgrastim (identified through HCPCS codes)...
Re: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniadoi:10.1080/13696998.2018.1452747Mark Bensink...
In the frst cycle, fever episodes occurred in 6.6% of patients in the biosimilar arm, com- pared with 2.8% in the reference arms, most of which resolved on the same day, with a maximum duration of 2 days in both arms. One or more episodes of FN were reported in 4.7% and 1.9% ...